Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Other Non Operating Income (2022 - 2025)

Historic Other Non Operating Income for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to $2.0 million.

  • ARS Pharmaceuticals' Other Non Operating Income fell 2209.92% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year decrease of 322.75%. This contributed to the annual value of $11.4 million for FY2024, which is 1357.66% down from last year.
  • According to the latest figures from Q3 2025, ARS Pharmaceuticals' Other Non Operating Income is $2.0 million, which was down 2209.92% from $2.7 million recorded in Q2 2025.
  • Over the past 5 years, ARS Pharmaceuticals' Other Non Operating Income peaked at $3.8 million during Q1 2023, and registered a low of -$151000.0 during Q1 2022.
  • Moreover, its 4-year median value for Other Non Operating Income was $2.8 million (2024), whereas its average is $2.2 million.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first surged by 652127.66% in 2023, then crashed by 2270.79% in 2024.
  • Over the past 4 years, ARS Pharmaceuticals' Other Non Operating Income (Quarter) stood at $1.2 million in 2022, then skyrocketed by 164.99% to $3.1 million in 2023, then fell by 1.08% to $3.0 million in 2024, then crashed by 32.53% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, $2.7 million for Q2 2025, and $3.2 million during Q1 2025.